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Abstract
Background: Symptom control is an important consideration in the choice of treatment for patients with
recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Patients who demonstrate
objective tumour responses to platinum-based chemotherapy are more likely to have symptom relief than those
who do not have such responses. A phase III trial (EXTREME) showed that adding the epidermal growth factor
receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy
significantly prolongs progression-free and overall survival and increases response rate compared with platinum-
based chemotherapy alone. We report here the case of a 60-year old female with recurrent squamous cell
carcinoma of the gum who had rapid palliation of symptoms and reduction of facial disease mass following
treatment with a combination of carboplatin/5-fluorouracil (5-FU) and cetuximab.
Case presentation: The patient was diagnosed with T4N0 M0 disease of the oral cavity in November 2006 and
underwent surgery, with R0 resection, followed by adjuvant radiotherapy and concomitant cisplatin chemotherapy.
Around 3 months later, the disease recurred and the patient had severe pain (9/10 on a visual pain scale), marked
facial oedema and a palpable facial mass of 89 mm. The patient received 4 21-day cycles of carboplatin (AUC 5), 5-
FU (1,000 mg/m
2/day for 4 days) and cetuximab (400 mg/m
2 initial dose followed by subsequently weekly doses
of 250 mg/m
2), with continuation of cetuximab monotherapy at the end of this time, and pain relief with topical
fentanyl and oral morphine. After 7 days of treatment, pain had reduced to 2/10, with discontinuation of morphine
after 4 days, and the facial mass had reduced to 70 mm. After 2 cycles of treatment, the facial mass had decreased
to 40 mm. After 3 cycles of treatment, pain and facial oedema had resolved completely and a cervical computed
tomography scan showed a marked reduction in tumour mass. Cetuximab monotherapy was continued
uninterrupted for 7 months.
Conclusion: This case illustrates the rapid reduction of tumour mass and disease-associated pain and oedema that
can be achieved with a combination of platinum-based chemotherapy and cetuximab in recurrent and/or
metastatic SCCHN.
Background
Cetuximab (Erbitux®) is an IgG1 epidermal growth fac-
tor receptor (EGFR)-targeting monoclonal antibody
which has been shown in phase III trials to improve the
survival of patients with squamous cell carcinoma of the
head and neck (SCCHN) when combined with first-line
platinum-based chemotherapy in recurrent and meta-
static disease [1] and when combined with radiotherapy
for the treatment of locoregionally advanced disease
[2,3]. In the phase III EXTREME trial in recurrent and
metastatic SCCHN, first-line treatment with a combina-
tion of platinum (cisplatin or carboplatin), 5-fluorouracil
(5-FU) and cetuximab not only significantly prolonged
progression-free and overall survival, compared with
platinum-based chemotherapy alone, but also increased
the overall tumour response rate by 16 percentage
points (36% with cetuximab/platinum/5-FU vs 20% with
platinum/5-FU alone) [1]. The tolerability of the two
regimens was similar, with a few exceptions. As
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any medium, provided the original work is properly cited.anticipated, grade 3/4 skin reactions and infusion-related
reactions were confined to the cetuximab plus platinum-
based chemotherapy arm of the trial. In addition, there
w e r es i g n i f i c a n t l ym o r ec a s e so fg r a d e3 / 4s e p s i sa n d
hypomagnesaemia in the cetuximab/platinum/5-FU arm,
compared with platinum-based chemotherapy alone,
although the absolute numbers of patients were small.
The effect of treatment on tumour response in this trial
suggests that the combination of cetuximab and plati-
num-based chemotherapy may be particularly useful for
symptomatic relief. We present here the case report of a
patient with recurrent squamous cell carcinoma of the
gum who derived rapid palliation of symptoms following
treatment with a combination of cetuximab, carboplatin
and 5-FU.
Case presentation
Initial diagnosis
In August 2006, a 60-year old Caucasian female (date of
birth 02 February 1946) presented with a left paraman-
dibular mass. Following a physical examination, cervical
computed tomography (CT) scan and biopsy, a diagno-
sis of squamous cell carcinoma of the gum was made
(November 2006). The patient had type II diabetes but
had no history of smoking or regular alcohol consump-
tion. On 11 December 2006, the patient underwent sur-
gery comprising left mandibulectomy and left lip
commissurotomy, with facial dermis resection, pectoral
flap reconstruction and left supraomohyoid lymphade-
nectomy, and a tracheotomy. Pathological examination
revealed grade 1 squamous cell carcinoma, 4.5 cm dia-
meter by 4.0 cm deep, with skin extension throughout
the mandibular border and involvement of the jaw bone.
There was no lymph node involvement and no metas-
tases were detected. Disease was staged as pT4N0 M0
following a thoracic X-ray. Tumour resection margins
were free of disease. From 07 February 2007 to 26
March 2007, the patient received adjuvant radiotherapy
(66 Gy) plus 3 doses of concomitant cisplatin (100 mg/
m
2, days 1, 22 and 43).
Disease recurrence
Two and a half months later (08 June 2007), the patient
presented at the emergency unit with intense pain in
her left hemiface. The patient was prescribed pain man-
agement with diclofenac (100 mg/12 hours, by supposi-
tory), gabapentin (300 mg/8 hours, orally) and fentanyl
(25 μg/72 hours, topical administration), supplemented
with additional doses of morphine as required (5 mg,
orally). On the 18 June 2007, the patient made an initial
v i s i tt oo u rc l i n i c .T h ep a t i e n t ’s pain had been con-
trolled but she now reported symptoms of left periorbi-
tal parasthesia and grade 1 asthenia. On physical
examination, the patient was assessed as having a
Karnofsky performance status of 80%. Left hemifacial,
lip, periorbital and cervical oedema were recorded. A
cervical, contrast-enhanced CT scan on 19 June 2007
revealed a bulky, expansive soft-tissue mass, with central
necrosis, extending from the left of the suprazygomatic
masticator space to the masseter muscle insertion site.
The temporalis, masseter and medial pterigoid muscles
were infiltrated. The lesion was close to the maxilla and
mandibular ramus. Cortical bone erosion was excluded.
These findings were compatible with recurrent disease
(Figure 1).
Treatment regimen for recurrent disease
After assessing the extent of the disease recurrence and
the structures involved, a multidisciplinary committee
concluded that local treatment, such as salvage surgery
or re-irradiation, would not be possible. Palliative treat-
ment with chemotherapy was considered the best option
and the patient agreed to this management approach.
The patient was scheduled to receive treatment accord-
ing to the regimen used in the investigational arm of
t h eE X T R E M Et r i a l .T h ec h o i c eo fp l a t i n u ma g e n tw a s
based on the fact that the patient had previously
received cisplatin in combination with radiotherapy for
locally advanced disease and that her glomerular filtra-
tion rate was 59 mL/min. The patient received 4 21-day
cycles of treatment with carboplatin (AUC 5), 5-FU
(1,000 mg/m
2/day, continuous infusion for 4 days) and
cetuximab (initial dose 400 mg/m
2,w i t hs u b s e q u e n t
weekly doses of 250 mg/m
2). Weekly cetuximab mainte-
nance therapy was continued following the end of the 4
cycles. Analgesia comprised topical fentanyl (50 μg/72
hours) and oral morphine (2.5 mg/4 hours) as required.
Response to treatment
Immediately prior to treatment (09 July 2007), the
patient’s condition had deteriorated since her first visit
to the clinic and she reported severe pain, registering 9/
10 on a visual pain scale, which was not controlled with
analgesia. She had difficulty chewing and required her
food to be mashed. Other symptoms included grade 2
asthenia and grade 1 anorexia. Physical examination
revealed a reduction in the patient’sK a r n o f s k yp e r f o r -
mance status (to 60%), an increase in facial oedema and
the presence of a palpable facial mass (89 mm
diameter).
After 4 days of treatment, the patient reported a
reduction in pain and the use of oral morphine was dis-
continued (Table 1). After 7 days of treatment, the
patient reported the pain to be controlled (2/10 on the
visual scale) with topical fentanyl (50 μg/72 hours) and
diclofenac (100 mg/12 hours, by suppository), and there
was a reduction in the facial mass to 70 mm in dia-
meter. After 2 cycles of treatment, labial and periorbital
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in the facial mass to 40 mm in diameter. After 3 cycles
of treatment, the patient reported no pain (0/10 on the
visual scale), leading to discontinuation of fentanyl, and
the facial oedema had resolved. The patient also
reported an improvement in the ability to chew food. A
cervical, contrast-enhanced CT scan at this stage (03
September 2007) revealed a marked reduction of the
solid lesion. A large area of necrosis, with peripheral
enhancing, was observed at the masticator space (Figure
2). A partial tumor remission was considered.
Cetuximab maintenance therapy was continued unin-
terrupted for 7 months. At this time, it was stopped for
3 weeks following the development of NCI-CTCAE
(National Cancer Institute-Common Terminology Cri-
teria for Adverse Events, Version 3.0) grade 2 mucositis
and grade 2 acne-like rash on the patient’s scalp.
On the 17 March 2008, the mucositis had resolved
and the skin toxicity had reduced to grade 1. How-
ever, there was a return of hemifacial pain (4/10 on
the pain visual scale), for which the patient received
topical fentanyl (25 μg/72 hours). Following reintro-
duction of cetuximab monotherapy, there was a
reduction in pain (2/10 on the visual scale). Cetuxi-
mab-associated skin reactions on the scalp were con-
trolled by topical treatment, according to the protocol
at our centre. Grade 1 reactions were managed by the
use of hydrating cream, topical corticosteroid cream
(0.5% betamethasone, twice a day) and/or topical anti-
biotic cream for acne-like rash, with oral antihista-
mines to control itch. For grade 2 reactions, topical
corticosteroid cream (0.5% betamethasone, twice a
day) was used, with the topical antibiotic cream
mupirocin (twice a day) for ulceration and infection,
and oral antihistamines to control itch.
On 27 May 2008 cetuximab was discontinued follow-
ing a CT scan showing signs of tumour progression.
Pain had been controlled up to this point on topical fen-
tanyl (25 μg/72 hours). The patient died from disease
progression on 06 June 2008.
Figure 1 Pre-treatment axial cervical contrast-enhanced computed tomography scan. The scan shows a bulky, expansive, soft-tissue mass
at the masticator space with heterogeneous enhancing and central necrosis. The infiltration of the masseter and medial pterigoid muscles is
seen.
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More than 50% of newly diagnosed patients with head
and neck cancer are not cured with standard treatment
approaches and will suffer local (more than 80%) and/
or distant (less than 15%) relapse despite appropriate,
aggressive therapy [4]. For selected patients with a sin-
gle, non-bulky recurrence, salvage surgery can be con-
sidered, although this is likely to result in some degree
of functional deficit. An alternative option is re-irradia-
tion, with or without concurrent chemotherapy, which
may be beneficial in terms of locoregional control and
survival, but which is associated with substantial toxi-
city. Indeed, in general, the use of re-irradiation should
be limited to the setting of a clinical trial [5]. When
local treatment is not an appropriate option, single-
agent or combination chemotherapy, is the standard
treatment choice for good performance status patients.
For the majority of patients with a poor performance
status (Eastern Cooperative Oncology Group [ECOG]
2 or worse, equivalent to Karnofsky performance status
60% or less [6]), like the patient discussed here, the
only real option is best supportive care.
In patients receiving chemotherapy, the most com-
monly used schedule is one based on cisplatin
combinations. For many years investigators have
attempted to identify the gold standard first-line treat-
ment, and randomised trials have compared the effects of
cisplatin-based chemotherapy with other standard
approaches or other cisplatin-based combinations [7,8].
In terms of response rate, combination chemotherapy
was superior to monotherapy, but did not improve survi-
val. In addition, cisplatin-based combination chemother-
apy was associated with more toxicity than monotherapy.
Thus, for 30 years, in recurrent head and neck cancer, no
first-line combination chemotherapy regimen had
demonstrated a survival advantage over platinum-based
chemotherapy. Therefore, the best option for these
patients was to be treated within the context of a clinical
trial utilizing therapy containing molecules against new
targets, such as cetuximab, which was used in combina-
tion with a platinum agent and 5-FU in the EXTREME
trial [1].
In our case report, adding cetuximab to carboplatin/5-
FU led to a rapid reduction in the size of the facial mass,
in facial oedema and in pain. Within 7 days of treatment,
the patient’s pain had reduced from 9/10 on a visual scale
to 2/10 and after 3 cycles of treatment, pain was controlled
without pain relief. Within 2 cycles of treatment, the facial
Figure 2 Axial contrast-enhanced cervical computed tomography scan after 3 cycles of cetuximab plus platinum-based chemotherapy.
The scan shows a marked reduction in the tumor. A large hypodense area with air bubbles and peripheral enhancing corresponding to necrosis
is seen in the masticator space. A partial tumor remission was considered.
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ment initiation. The patient also reported an improvement
in the ability to chew food. In addition, it was possible to
administer cetuximab continuously as monotherapy for 7
months, during which time symptoms remained alleviated.
It was eventually interrupted due to grade 2 mucositis and
skin reactions. It is notable that facial pain returned on
cetuximab cessation and decreased again following cetuxi-
mab resumption.
The response to the regimen of cetuximab and carbopla-
tin/5-FU is particularly encouraging in view of the fact that
it was achieved in a tumor that had less than six months
earlier been irradiated and that had previously progressed
rapidly on a combination of cisplatin and radiotherapy.
An association between platinum/5-FU chemotherapy,
tumour response and symptom control in patients with
recurrent and/or metastatic SCCHN was reported over
ten years ago by Constenla et al.[9]. They reported that
patients achieving an objective tumour response to
treatment were more likely to obtain some symptom
relief and improve their performance status than those
not achieving a response. The phase III EXTREME trial
showed that adding cetuximab to platinum-based che-
motherapy significantly improved response rate com-
pared with platinum-based chemotherapy alone [1]. A
quality of life analysis of this trial reported that adding
cetuximab to platinum/5-FU did not adversely affect
global quality of life [10]. There were also some
improvements with cetuximab/platinum-based therapy
compared with platinum-based therapy alone in a num-
ber of parameters, including pain and swallowing [10].
The results of our case report are significant in that
they demonstrate the speed with which symptom relief,
associated with tumour mass reduction, can be achieved
with cetuximab/carboplatin/5-FU for a patient with
recurrent and/or metastatic SCCHN whose quality of
life is severely compromised by their disease.
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Table 1 Efficacy and toxicity of treatment
Treatment cycle Effect of treatment on signs and symptoms Adverse events
Pre-treatment Pain 9/10*
Facial mass 89 mm
N/A
1 Pain reduction to 2/10* after 7 days, with discontinuation of oral
morphine after 4 days
Reduction of facial mass to 70 mm
Grade 2 nausea
2 Labial and periorbital facial oedema reduced
Reduction of facial mass to 40 mm
Grade 2 nausea
Grade 2 neutropenia
Next treatment cycle delayed by
one week
3 Pain resolved (0/10)* and pain relief discontinued
Facial oedema resolved
CT scan: partial tumour remission, with marked reduction of
retromandibular mass
Grade 2 anaemia
4 No pain relief requirement Grade 2 anorexia
Grade 2 vomiting
Grade 2 asthenia
Grade 2 mucositis
Grade 3 anaemia (requiring red cell
transfusion)
Grade 1 acne-like rash (facial)
Cetuximab maintenance
(7 continuous months of
treatment)
No pain relief requirement Grade 2 mucositis
Grade 2 acne-like rash (painful
lesions on the scalp)
Cetuximab discontinued for 3 weeks
*Pain was assessed using a visual pain scale with a range from 0 to 10: the higher the score, the more severe the pain. CT = computed tomography.
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